title: Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995.
abstract: Treatment of severe bleeding and the performance of surgery in haemophilia patients with inhibitors creates severe problems. It is generally agreed that treatment is most effective if circulating levels of factor VIII/IX can be achieved long enough for control of haemostasis. Immunoadsorption with protein A for the removal of inhibitor has improved treatment for patients with initial inhibitor titres too high to neutralize by infusion alone. This is a summary of our experience in Malmö regarding immunoadsorption and haemostasis. A total of 19 applications with immunoadsorption in 10 patients were performed. On all occasions it was possible to eliminate totally the inhibitor or reduce it to low levels that could easily be neutralized with factor concentrate. Haemostatic levels of coagulation factors could be maintained for 5-9 days in all but one patient. This period was sufficient to stop ongoing haemorrhage or prevent excessive bleeding at surgical interventions.
authors.affiliation: Department for Coagulation Disorders, University of Lund, University Hospital, Malmö, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Freiburghaus
authors.forename: E
authors.initials: E
authors.lastname: Berntorp
authors.forename: M
authors.initials: M
authors.lastname: Ekman
authors.forename: M
authors.initials: M
authors.lastname: Gunnarsson
authors.forename: B M
authors.initials: BM
authors.lastname: Kjellberg
authors.forename: I M
authors.initials: IM
authors.lastname: Nilsson
mesh_terms: D005164:Factor IX / Q000037:antagonists & inhibitors*; D005169:Factor VIII / Q000037:antagonists & inhibitors*; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006487:Hemostasis / Q000502:physiology*; D006801:Humans; D007163:Immunosorbent Techniques; D011183:Postoperative Complications / Q000517:prevention & control; D013548:Sweden; D014945:Wound Healing / Q000187:drug effects
chemical_list: D005169:Factor VIII; D005164:Factor IX